智通财经APP讯，ST诺泰(688076.SH)发布第三季度业绩预告，预计2025年第三季度实现归属于母公司 所有者的净利润1.3亿元至1.4亿元，同比增加5.62%到13.74%。报告期内，公司贯彻"时间领先、技术领 先"的经营理念，各项主营业务有序开展，净利润实现稳健增长。 ...

Core Viewpoint - ST Nuotai (688076.SH) expects a net profit attributable to shareholders of the parent company to be between 130 million to 140 million yuan in Q3 2025, representing a year-on-year increase of 5.62% to 13.74% [1] - The company also anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be between 130 million to 140 million yuan, with a year-on-year increase of 3.76% to 11.74% [1] Financial Performance - The projected net profit for Q3 2025 is estimated to be between 130 million to 140 million yuan [1] - The expected year-on-year growth rates for net profit are between 5.62% to 13.74% [1] - The anticipated net profit, excluding non-recurring items, is also projected to be between 130 million to 140 million yuan, with growth rates of 3.76% to 11.74% [1] Business Strategy - The company adheres to the business philosophy of "time-leading, technology-leading," ensuring orderly development of its main businesses [1] - The implementation of this strategy has contributed to stable growth in net profit [1]

Group 1 - The core viewpoint of the article is that ST Nuotai (SH 688076) expects a net profit of 130 million to 140 million yuan for the third quarter of 2025, representing a year-on-year increase of 5.62% to 13.74% [1] - The increase in net profit is attributed to the company's implementation of the "time-leading, technology-leading" business philosophy, which has led to steady growth in its main business operations [1] - For the year 2024, ST Nuotai's revenue composition is heavily weighted towards the pharmaceutical manufacturing industry, accounting for 99.88% of total revenue, with other businesses making up only 0.12% [1] Group 2 - As of the report, ST Nuotai has a market capitalization of 12.7 billion yuan [2]

证券代码：688076 证券简称：ST 诺泰 公告编号：2025-068 江苏诺泰澳赛诺生物制药股份有限公司 2025年第三季度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 7 月 1 日至 2025 年 9 月 30 日。 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年第三季度实现归属于母公司所有者 的净利润为 13,000 万元到 14,000 万元，与上年同期（法定披露数据）相比，将 增加 691.45 万元到 1,691.45 万元，同比增加 5.62%到 13.74%。 （2）预计 2025 年第三季度实现归属于母公司所有者的扣除非经常性损益的 净利润为 13,000 万元到 14,000 万元，与上年同期（法定披露数据）相比，将增 加 470.61 万元到 1,470.61 万元，同比增加 3.76%到 11.74%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 2024 年第三季度，公司利润 ...

Group 1 - Recent information disclosure violations have been reported by companies such as Jinsheng New Materials, *ST Aowei, and ST Nuotai, leading to significant market value loss for investors and undermining trust in the capital market's integrity [1][2] - Jinsheng New Materials received a warning letter from the Zhejiang Securities Regulatory Bureau for multiple violations, including failure to disclose related party transactions in a timely manner and mixing management with its actual controller [2] - The company has faced continuous losses, with reported revenues increasing from 243 million yuan in 2022 to 333 million yuan in 2024, but net profits showing losses of over 69 million yuan cumulatively during the same period [2] Group 2 - ST Nuotai was found to have inflated revenue by 30 million yuan through non-commercial transactions in 2021, which misled investors regarding its financial health [3][4] - The company continued to use false financial data in its convertible bond issuance documents in 2023, further misleading investors and disrupting normal financing order in the capital market [4] - Investors who purchased ST Nuotai shares between April 28, 2022, and October 23, 2024, may seek compensation for losses [4] Group 3 - *ST Aowei announced a significant downward revision of its financial forecasts, with net profit losses expected to widen from an initial estimate of 32 million to 45 million yuan to a range of 50 million to 75 million yuan [5] - The company's revenue forecast was also drastically reduced from 450 million to 520 million yuan down to 280 million to 299 million yuan [5] - Investors who bought shares between January 24, 2025, and April 21, 2025, may also pursue claims for compensation [5]

Group 1 - A new company, Wuxi Nuotai Biotechnology Co., Ltd., has been established with a registered capital of 750,000 RMB [1] - The legal representative of the company is Yu Yuxing [1] - The company's business scope includes sales of magnetic materials, research and development of new materials, manufacturing and sales of bio-based materials, and various sales of chemical products [1] Group 2 - The company is involved in the sales of medical devices, both Class I and Class II [1] - It also engages in import and export activities, including technology services, development, consulting, and promotion [1] - The company focuses on industrial enzyme preparations and bio-based material polymer technology research and development [1]

证券代码：688076 证券简称：ST 诺泰 公告编号：2025-067 江苏诺泰澳赛诺生物制药股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 9 月 5 日 （二） 股东会召开的地点：浙江省杭州市余杭区文一西路 1378 号杭州师范大学 科技园 E 座 12 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 207 | | --- | --- | | 普通股股东人数 | 207 | | 2、出席会议的股东所持有的表决权数量 | 135,496,040 | | 普通股股东所持有表决权数量 | 135,496,040 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 42.8715 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量 ...

诺泰生物 2025 年第一次临时股东会法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 江苏诺泰澳赛诺生物制药股份有限公司 2025 年第一次临时股东会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 关 于 江苏诺泰澳赛诺生物制药股份有限公司 2025 年第一次临时股东会 法律意见书 致：江苏诺泰澳赛诺生物制药股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受江苏诺泰澳赛诺生物制 药股份有限公司（以下简称"公司"）委托，指派律师出席公司 2025 年第一次 临时股 ...

Group 1 - The stock prices of Japan's five major trading companies have reached a 20-year high, driven by Warren Buffett's investment five years ago, creating excitement and hesitation among investors [1] - Since Buffett disclosed his investment in 2020, the average increase of the five trading companies has reached 320%, significantly outperforming the Tokyo Stock Exchange index [1] - Despite the positive market sentiment from Buffett's recent increase in Mitsubishi Corporation shares, professional institutions are expressing concerns about the current high valuation levels [1] Group 2 - The article discusses the phenomenon of market corrections during bull markets, highlighting that small adjustments do not typically trigger panic among investors [2] - Historical examples from the ChiNext index illustrate that significant declines can occur even in a bull market, leading to potential losses for investors who buy at the wrong time [2] Group 3 - The white liquor sector experienced a sharp decline following a government ban, with an average drop of over 6% in 20 trading days, while the Shanghai Composite Index saw a slight increase [3][5] - The article emphasizes that stock price performance is determined more by institutional investor behavior than by the presence of good or bad news [5][7] Group 4 - The case of Notai Bio, which saw a significant rebound after being placed under special treatment, illustrates the "bad news is good news" phenomenon, as institutional investors had already positioned themselves before the news broke [8][10] - The article suggests that understanding institutional behavior is crucial for predicting stock price movements, rather than relying solely on news events [10] Group 5 - The article concludes by advising investors to avoid blindly following prominent investors like Buffett and to focus on quantitative data rather than news [11] - Establishing a personal decision-making framework and finding suitable tools and methods are essential for navigating the information overload in the market [11]

Core Viewpoint - The company is preparing for its first extraordinary general meeting of shareholders in 2025, focusing on maintaining shareholder rights and ensuring orderly proceedings during the meeting [1][2]. Meeting Procedures - All attendees must adhere to legal obligations and meeting discipline to protect shareholder rights and maintain order [2]. - Only authorized personnel, including shareholders, directors, supervisors, and invited guests, are allowed to enter the meeting venue [2]. - Shareholders are responsible for their own expenses related to attending the meeting, and no gifts or accommodations will be provided by the company [2]. - Attendees must arrive 30 minutes before the meeting to complete registration and present identification [3]. Voting and Rights - Shareholders have the right to speak, inquire, and vote during the meeting, with specific procedures for registration and time limits for speaking [3][4]. - Voting will be conducted through both on-site and online methods, with results announced after the meeting [5]. - Shareholders must express their opinions on non-cumulative voting proposals as "agree," "disagree," or "abstain" [4]. Agenda Items - The first agenda item involves changing the accounting firm from Zhongtianyun to Zhongxi for the 2025 financial report and internal control audit, citing the need for independence after years of service from the previous firm [6][7]. - The second agenda item proposes the cancellation of the supervisory board and amendments to the company's articles of association, transferring supervisory responsibilities to the audit committee [13][14]. Company Structure Changes - The company plans to revise its articles of association to reflect the cancellation of the supervisory board and the transfer of its powers to the audit committee [14][15]. - The registered capital of the company will increase to RMB 316,051,897 following the proposed changes [16]. Communication and Compliance - The company has communicated with both the outgoing and incoming accounting firms regarding the change, ensuring all parties are aware and have no objections [12]. - The audit committee has reviewed and approved the change in accounting firms, emphasizing the qualifications and independence of the new firm [12].